Big generic drug news today, and it’s not good. If you suffer from rheumatoid arthritis or psoriasis and have been looking forward to Enbrel going generic next year, you may have to wait a little longer. Actually, you may have to wait a lot longer for a generic version of Enbrel to come out. Amgen has announced that it has won a new patent for its blockbuster arthritis drug, which means that there might not be a generic version of Enbrel out until 2028.
Enbrel was due to come off patent next October, and a number of pharmaceutical companies have been gunning to bring out generic versions of Enbrel, including Merck. Although Amgen had been depending on some patent arguments to hold up their patents for another 5 years, we find it more than a little outrageous that Amgen is going to try to hold onto Enbrel for seventeen more years!
According to the the Arthritis Foundation, rheumatoid arthritis is a chronic disease, mainly characterized by inflammation of the lining, or synovium, of the joints. It can lead to long-term joint damage, resulting in chronic pain, loss of function and disability. Considering a thirty-day supply of brand-name Enbrel is currently running almost $1,000, we know this news is devastating to many arthritis patients who were looking for more affordable options. You can be sure we’ll be watching this one to see if Amgen’s shiny new Enbrel patent holds up!
Do you or a loved one use Enbrel to treat arthritis? Tell us about it!
- Merck Moves to Start a Generic Version of Arthritis Drug Enbrel
- Drug Savings Tip: Arthritis-Sufferers, Have You Tried the Enbrel Support Card?
- Huge Generic Drug News! FDA Grants Tentative Approval for Generic Version of Cholesterol Drug Crestor
- Generic Drug News: Strattera Patent Upheld, No Generic Strattera Until 2017
- Generic Drug News: Sandoz Files Suit to Release Generic Version of Diabetes Drug Prandin